Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Accumulated Depreciation (2016 - 2023)

Historic Accumulated Depreciation for Kyntra Bio (KYNB) over the last 10 years, with Q4 2023 value amounting to $113.0 million.

  • Kyntra Bio's Accumulated Depreciation fell 1222.0% to $113.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $113.0 million, marking a year-over-year decrease of 1222.0%. This contributed to the annual value of $113.0 million for FY2023, which is 1222.0% down from last year.
  • Per Kyntra Bio's latest filing, its Accumulated Depreciation stood at $113.0 million for Q4 2023, which was down 1222.0% from $128.7 million recorded in Q4 2022.
  • In the past 5 years, Kyntra Bio's Accumulated Depreciation ranged from a high of $128.7 million in Q4 2022 and a low of $93.2 million during Q1 2019
  • In the last 5 years, Kyntra Bio's Accumulated Depreciation had a median value of $109.4 million in 2020 and averaged $109.0 million.
  • In the last 5 years, Kyntra Bio's Accumulated Depreciation soared by 5393.49% in 2019 and then plummeted by 1222.0% in 2023.
  • Over the past 5 years, Kyntra Bio's Accumulated Depreciation (Quarter) stood at $100.4 million in 2019, then rose by 10.84% to $111.2 million in 2020, then increased by 8.77% to $121.0 million in 2021, then grew by 6.34% to $128.7 million in 2022, then dropped by 12.22% to $113.0 million in 2023.
  • Its Accumulated Depreciation was $113.0 million in Q4 2023, compared to $128.7 million in Q4 2022 and $121.0 million in Q4 2021.